Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
(Wilding et al., NEJM, 2021 PubMed: 33567185) STEP 2 Trial (2021) In patients with both obesity and type 2 diabetes, semaglutide 2.4 mg produced mean weight loss of 9.6% versus 3.4% with placebo at 68 weeks
Other big (aka investable) companies in the GLP 1 race is: Amgen Amgen is developing MariTide , a monthly injectable, currently in Phase 3 trials
For a more detailed overview, our page on retatrutide side effects covers what has been observed so far
According to the World Health Organization, over one billion people will be obese by 2022, with 650 million adults, 340 million adolescents, and 39 million children being the most obese
US$ 23.25
US$ 25.20
US$ 28.33
